High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia

被引:0
作者
Diana Torres
Muhammad Usman Rashid
Fabian Gil
Angela Umana
Giancarlo Ramelli
Jose Fernando Robledo
Mauricio Tawil
Lilian Torregrosa
Ignacio Briceno
Ute Hamann
机构
[1] German Cancer Research Center,Division of Molecular Genome Analysis
[2] Pontificia Universidad Javeriana,Unidad de Epidemiología Clínica y Bioestadística
[3] Pontificia Universidad Javeriana,Instituto de Genética Humana
[4] Shaukat Khanum Memorial Cancer Hospital and Research Center,Departamento de Cirugía
[5] Clínica del Country,Facultad de Medicina, Departamento de Cirugía
[6] Pontificia Universidad Javeriana,undefined
来源
Breast Cancer Research and Treatment | 2007年 / 103卷
关键词
Germline mutations; Hereditary breast/ovarian cancer; Hispanics; Colombia;
D O I
暂无
中图分类号
学科分类号
摘要
In South America, a high proportion of the population is of Hispanic origin with an important representation in Colombia. Since nothing is known about the contribution of BRCA1 and BRCA2 germline mutations to hereditary breast/ovarian cancer in the Hispanic population from Colombia, we conducted the first study of 53 breast/ovarian cancer families from this country. Comprehensive BRCA mutation screening was performed using a range of techniques, including DHPLC, SSCP, and PTT, followed by DNA sequencing analysis. Thirteen deleterious germline mutations (24.5%) were identified in 53 families, comprising eight in BRCA1 and five in BRCA2. The two recurrent BRCA1 mutations, 3450 delCAAG and A1708E, accounted for 100% of all BRCA1 mutations identified in this cohort and the recurrent 3034 delACAA BRCA2 mutation for 40% of all BRCA2 mutations. Haplotype analyses suggested that each of these mutations has arisen from a common ancestor. The prevalence of BRCA1 or BRCA2 mutations was 50% in multiple case breast cancer families, and was 33% for the breast-ovarian cancer families. Our findings show that BRCA mutations account for a substantial proportion of hereditary breast/ovarian cancer in Colombia. The spectrum of mutations differed completely to that previously reported in Hispanic families of predominantly Mexican origin from Southern California [1] suggesting that specific genetic risk assessment strategies for the different Hispanic populations in South America and in the United States need to be developed.
引用
收藏
页码:225 / 232
页数:7
相关论文
共 50 条
  • [41] BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families
    Peixoto, Ana
    Salgueiro, Natalia
    Santos, Catarina
    Varzim, Graca
    Rocha, Patricia
    Soares, Maria Jose
    Pereira, Deolinda
    Rodrigues, Helena
    Bento, Maria Jose
    Fraguas, Antonio
    Moura, Graca
    Regateiro, Fernando
    Castedo, Sergio
    Teixeira, Manuel R.
    FAMILIAL CANCER, 2006, 5 (04) : 379 - 387
  • [42] Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review
    Andres Ossa, Carlos
    Torres, Diana
    ONCOLOGIST, 2016, 21 (07) : 832 - 839
  • [43] Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer
    Liu, Guoyan
    Yang, Da
    Sun, Yan
    Shmulevich, Ilya
    Xue, Fengxia
    Sood, Anil K.
    Zhang, Wei
    PHARMACOGENOMICS, 2012, 13 (13) : 1523 - 1535
  • [44] Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer
    Ratajska, Magdalena
    Koczkowska, Magdalena
    Zuk, Monika
    Gorczynski, Adam
    Kuzniacka, Alina
    Stukan, Maciej
    Biernat, Wojciech
    Limon, Janusz
    Wasag, Bartosz
    ONCOTARGET, 2017, 8 (60) : 101325 - 101332
  • [45] BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan
    Abu-Helalah, Munir
    Azab, Belal
    Mubaidin, Rasmi
    Ali, Dema
    Jafar, Hanan
    Alshraideh, Hussam
    Drou, Nizar
    Awidi, Abdalla
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [46] High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered?
    Smith, Miriam J.
    Gifford, Franchesca L.
    Lalloo, Fiona
    Newman, William G.
    Evans, D. Gareth R.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (02) : 895 - 897
  • [47] Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer
    Kim, Haeyoung
    Cho, Dae-Yeon
    Choi, Doo Ho
    Choi, Su-Youn
    Shin, Inkyung
    Park, Won
    Huh, Seung Jae
    Han, Sung-Hee
    Lee, Min Hyuk
    Ahn, Sei Hyun
    Son, Byung Ho
    Kim, Sung-Won
    Haffty, Bruce G.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (03) : 1315 - 1326
  • [48] BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing Testing for Hereditary Breast-Ovarian Cancer
    Hall, Michael J.
    Reid, Julia E.
    Burbidge, Lynn A.
    Pruss, Dmitry
    Deffenbaugh, Amie M.
    Frye, Cynthia
    Wenstrup, Richard J.
    Ward, Brian E.
    Scholl, Thomas A.
    Noll, Walter W.
    CANCER, 2009, 115 (10) : 2222 - 2233
  • [49] Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
    Wojcik, P.
    Jasiowka, M.
    Strycharz, E.
    Sobol, M.
    Hodorowicz-Zaniewska, D.
    Skotnicki, P.
    Byrski, T.
    Blecharz, P.
    Marczyk, E.
    Cedrych, I.
    Jakubowicz, J.
    Lubinski, J.
    Sopik, V.
    Narod, S.
    Pierzchalski, P.
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2016, 14
  • [50] BRCA2 founder mutation in Slovenian breast cancer families
    Krajc, M
    De Grève, J
    Goelen, G
    Teugels, E
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 (12) : 879 - 882